A Study to Evaluate MAR002 for Acromegaly
NCT07641179 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72
Last updated 2026-06-12
Summary
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly
Conditions
Interventions
- DRUG
-
MAR002
Subcutaneous injection
- DRUG
-
Subcutaneous injection
Sponsors & Collaborators
-
Marea Therapeutics
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-31
- Primary Completion
- 2027-08-31
- Completion
- 2027-12-31
- FDA Drug
- Yes
More Related Trials
-
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
NCT05192382 ·Status: TERMINATED ·Phase: PHASE3
-
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
NCT04076462 ·Status: COMPLETED ·Phase: PHASE3
-
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
NCT02354508 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
NCT00994214 ·Status: TERMINATED ·Phase: PHASE2
-
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
NCT00171730 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
NCT01995734 ·Status: APPROVED_FOR_MARKETING
-
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
NCT07623824 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
NCT03045302 ·Status: TERMINATED ·Phase: PHASE2
-
Octreotide Efficacy and Safety in First-line Acromegalic Patients
NCT00171886 ·Status: COMPLETED ·Phase: PHASE4
-
Pasireotide LAR and Pegvisomant Study in Acromegaly
NCT02668172 ·Status: UNKNOWN ·Phase: PHASE4
-
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
NCT00242541 ·Status: TERMINATED ·Phase: PHASE4
-
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
NCT04125836 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)
NCT07016802 ·Status: RECRUITING ·Phase: PHASE1
-
Acromegaly Treatment Quality of Life Study
NCT01732406 ·Status: COMPLETED
-
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
NCT07583563 ·Status: RECRUITING
-
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
NCT00635765 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
NCT00616551 ·Status: COMPLETED ·Phase: PHASE3
-
The Treatment and Natural History of Acromegaly
NCT00001981 ·Status: COMPLETED
-
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
NCT00376064 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients
NCT01562834 ·Status: COMPLETED ·Phase: PHASE4
-
Prediction of Tumor Shrinkage in Acromegaly
NCT00616408 ·Status: COMPLETED
-
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
NCT01673646 ·Status: COMPLETED ·Phase: PHASE2
-
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
NCT02229851 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
NCT01137682 ·Status: COMPLETED ·Phase: PHASE3